Mizuho Markets Americas LLC Reduces Stock Holdings in Kenvue Inc. $KVUE

Mizuho Markets Americas LLC cut its stake in Kenvue Inc. (NYSE:KVUE) by 48.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,153,935 shares of the company’s stock after selling 13,512,861 shares during the quarter. Kenvue comprises about 4.7% of Mizuho Markets Americas LLC’s portfolio, making the stock its 4th biggest position. Mizuho Markets Americas LLC’s holdings in Kenvue were worth $244,155,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. Aberdeen Group plc boosted its holdings in shares of Kenvue by 84.1% in the 3rd quarter. Aberdeen Group plc now owns 1,411,380 shares of the company’s stock valued at $22,914,000 after buying an additional 644,930 shares in the last quarter. Oak Thistle LLC bought a new position in shares of Kenvue during the 4th quarter worth approximately $1,563,000. Eubel Brady & Suttman Asset Management Inc. lifted its position in Kenvue by 39.7% during the third quarter. Eubel Brady & Suttman Asset Management Inc. now owns 1,371,886 shares of the company’s stock valued at $22,266,000 after acquiring an additional 389,704 shares during the last quarter. SG Americas Securities LLC lifted its position in Kenvue by 3,889.9% during the fourth quarter. SG Americas Securities LLC now owns 3,075,723 shares of the company’s stock valued at $53,056,000 after acquiring an additional 2,998,635 shares during the last quarter. Finally, ICICI Prudential Asset Management Co Ltd boosted its stake in Kenvue by 137.9% in the third quarter. ICICI Prudential Asset Management Co Ltd now owns 452,060 shares of the company’s stock valued at $7,337,000 after acquiring an additional 262,000 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Trading Up 0.5%

NYSE KVUE opened at $17.55 on Friday. The company has a fifty day simple moving average of $17.40 and a two-hundred day simple moving average of $17.42. The stock has a market cap of $33.69 billion, a P/E ratio of 20.64, a P/E/G ratio of 1.32 and a beta of 0.55. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $24.00. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same period in the previous year, the company earned $0.24 earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, analysts forecast that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th will be paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.7%. The ex-dividend date is Wednesday, May 13th. Kenvue’s payout ratio is presently 97.65%.

Insiders Place Their Bets

In other news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.59% of the company’s stock.

Analysts Set New Price Targets

KVUE has been the topic of several analyst reports. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $23.00 to $18.00 in a report on Friday, January 30th. UBS Group lowered their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Citigroup dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Finally, Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus target price of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.